

8. **(Twice amended)** An isolated proteinic or glycoprotein inhibitor of xylanase comprising an amino acid sequence at least 70% homologous to SEQ ID NO:1 or SEQ ID NO:2.

9. **(Twice amended)** The isolated inhibitor of claim 8, wherein the amino acid sequence is the N-terminal amino acid sequence of the protein or glycoprotein.

10. **(Twice amended)** The isolated inhibitor of claim 8 comprising an amino acid sequence at least 85% homologous to SEQ ID NO:1 or SEQ ID NO:2.

C' incl.  
11. **(Twice amended)** The isolated inhibitor of claim 10, wherein the amino acid sequence is the N-terminal amino acid sequence of the protein or glycoprotein.

12. **(Twice amended)** The isolated inhibitor of claim 7, comprising SEQ ID NO:1 or SEQ ID NO:2.

13. **(Twice amended)** The isolated inhibitor of claim 12, wherein SEQ ID NO:1 or SEQ ID NO:2 is the N-terminal amino acid sequence of the protein or glycoprotein.

---

#### REMARKS

Claims 6-13 have been amended to provide that the claimed inhibitor is an isolated inhibitor. Support for the amendments to the claims is found in the specification as filed.

#### I. Rejection under 35 U.S.C. § 101

The Examiner has rejected claims 6-13 under 35 U.S.C. § 101 on the assertion that the claims are directed towards non-statutory subject matter. Applicants have amended Claims 6 and 8 to recite "An isolated proteinic or glycoprotein inhibitor of xylanase..." and Claims 7 and 9 to 13 have been amended to recite the "isolated inhibitor of claim..." Applicants respectfully submit that amended Claims 6 to 13 are directed towards statutory subject matter and respectfully request withdrawal of the rejection to Claims 6-13 under 35 U.S.C. § 101.

#### II. Rejections Based on the Assertion that the Specification Does Not Satisfy the Written Description Requirement

The Examiner has rejected Claims 6 to 13 under 35 U.S.C. § 112, first paragraph on the assertion that the specification does not describe a sufficient number of species